Abstracts tagged "DMARDs"

Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: L10 • 2018 ACR/ARHP Annual Meeting
Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial
Timothy R.D.J. Radstake¹, Eefje H.M. van der Heijden², Frederique M. Moret³, Maarten R. Hillen⁴, Ana P. Lopes⁵, Toine Rosenberg⁶, Nard Janssen⁶, Aike A. Kruize⁷ and Joel A.G. van Roon³, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Oral-Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a systemic, progressive autoimmune disease characterized by secretory gland dysfunction which lacks effective therapy. Clinical trials in patients with…
Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Sytske Anne Bergstra¹, Lai-Ling Winchow², Elizabeth Murphy³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, João E. Fonseca⁶, Cornelia F. Allaart¹ and Robert B.M. Landewé⁷, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²University of the Witwatersrand, Johannesburg, South Africa, ³University Hospital Wishaw, Scotland, Wishaw, United Kingdom, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…
Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
Shubha Kollampare¹, C. Kent Kwoh^1,2, Wei-Hsuan Lo-Ciganic³, Lili Zhou^2,4, Erin L. Ashbeck² and Dominick Sudano¹, ¹Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, ⁴College of Pharmacy, University of Arizona, Tucson, AZ
Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…
Abstract Number: 2048 • 2018 ACR/ARHP Annual Meeting
In Vitro Proof-of-Concept of Pathobiology-Guided Therapy in Immune Mediated Inflammatory Arthritis
Morten Aagaard Nielsen¹, Bent Deleuran^2,3 and Tue Wenzel Kragstrup^2,3,4, ¹Of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Randers Regional Hospital, Randers, Denmark
Background/Purpose: Immune mediated inflammatory arthritis are very heterogeneous diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA). The available biological and targeted synthetic…
Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Vibeke Strand¹, Nemanja Damjanov², Craig Scoville³, Namita Tundia⁴, Heidi S. Camp⁴, Kun Chen⁴, Jessica Suboticki⁴ and Ronald van Vollenhoven⁵, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, ³Idaho Falls Arthritis Clinic, Idaho Falls, ID, ⁴AbbVie Inc., North Chicago, IL, ⁵Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…
Abstract Number: 546 • 2018 ACR/ARHP Annual Meeting
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
Peter C. Taylor¹, Yoshiya Tanaka², Anabela Cardoso³, Jinglin Zhong⁴, Yun-Fei Chen³, Jennifer Lynn Workman³, Liliana del Carmen Morales⁵ and Michael Schiff⁶, ¹Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴IQVIA, Morrisville, NC, ⁵INStituto Reumatologica Strusberg, Cordoba, Argentina, ⁶University of Colorado, Greenwood Village, CO
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries including…
Abstract Number: 1227 • 2018 ACR/ARHP Annual Meeting
Indicator Opportunistic Infections after Biological Treatment in Rheumatoid Arthritis, 10 Years Follow up in Clinical Practice
Leticia Leon^1,2, Marina Peñuelas³, Francisco Javier Candel³, Dalifer Freites Núñez⁴, Luis Rodriguez-Rodriguez⁵, Zulema Rosales Rosado⁶ and Lydia A Alcazar⁷, ¹Rheumatology Department, Hospital Clínical San Carlos, and IdISSC, Madrid, Spain, ²Health Sciences, Universidad Camilo Jose Cela, Madrid, Spain, ³Microbiology, Microbiology Department. Hospital Clínico San Carlos, Madrid, Spain., Madrid, Spain, ⁴Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁶Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ⁷Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) may be associated with opportunistic infections. Our purposes were to describe their incidence in Rheumatoid Arthritis (RA) taking bDMARDs,…
Abstract Number: 2185 • 2018 ACR/ARHP Annual Meeting
Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
Andrew Hresko¹, Zhi Zhang², Joshua Colls², Michael E Weinblatt², Nancy A. Shadick² and Daniel Solomon², ¹Tufts University School of Medicine, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) affects over 1 million Medicare enrollees. Despite the size of this population, costs for RA within Medicare remain poorly understood, especially…
Abstract Number: 2561 • 2018 ACR/ARHP Annual Meeting
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
Ana-Maria Orbai¹, Dafna D Gladman², Julie Birt³, Amanda M. Gellett³, Chen-Yen Lin³ and Tore Kvien⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Toronto, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements up to Week (Wk) 24 across several domains of PsA (including ACR20)…
Abstract Number: 560 • 2018 ACR/ARHP Annual Meeting
Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept
Hafiz Oko-osi¹, Machaon Bonafede², Mahdi Gharaibeh¹, Janna Manjelievskaia², Lorena Lopez-Gonzalez², David H. Collier¹ and Bradley S. Stolshek¹, ¹Amgen Inc., Thousand Oaks, CA, ²IBM Watson Health, Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease that requires long-term treatment to improve or maintain disease activity. Tumor necrosis factor inhibitors (TNFi), a…
Abstract Number: 1251 • 2018 ACR/ARHP Annual Meeting
Guideline Adherence for Perioperative Use of Immunosuppressive Medications in Patients with Rheumatologic Disease
Grace Berlin, Carolyn Casey, Susan Kim and James Ross, Rheumatology, Lehigh Valley Health Network, Allentown, PA
Background/Purpose: In response to the lack of clear data to dictate recommendations for use of DMARDs and biologic therapy in the perioperative period, The American…
Abstract Number: 2194 • 2018 ACR/ARHP Annual Meeting
Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China
Yongfu Wang¹, Hua Wei², Jing Yang³, Chun Li⁴, Rong Mu⁵, Bin Wu⁶, Hongzhi Wang⁷, Yong Wang⁸, Xiaohan Wang⁹, Huifang Guo¹⁰, Jing Xue¹¹, Jinli Ru¹², Xiafei Xin¹³, Fengxiao Zhang¹⁴, Lirong Kang¹, Hong Liu³, Xiaoling Liu¹⁵, Tong Xie¹⁶, Lingxun Shen¹⁷, Huiqin Yang¹⁸, Shouxin Li¹⁹, Fen Li²⁰, Fen Wang²¹, Rui Wu²², Yuan Liu²³, Hui Xiao²³, Yuhua Jia²³, Fei Xiao²³ and Jianlin Huang²⁴, ¹The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ²Northern Jiangsu People's Hospital, Yangzhou, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Peking University People's Hospital, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁶Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ⁷The First Hospital of Jiaxing, Jiaxing, China, ⁸The first Hospital Affiliated to AMU (Southernwest Hospital), Chongqing, China, ⁹Department of Rheumatology and Immunology, Anyang district hospital, Anyang, China, ¹⁰The Second Hospital of Hebei Medical University, Shijiazhuang, China, ¹¹88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹²The Second hospital of Shanxi Medical University, Taiyuan, China, ¹³Department of Rheumatology and Immunology, NingBo First Hospital, Zhejiang, Ningbo, China, ¹⁴Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, China, ¹⁵The 1st Affiliated Hospital of Guangzhou University of TCM, Guangzhou, China, ¹⁶Affiliated hospital of Guangdong medical University, Zhanjiang, China, ¹⁷Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, ¹⁸Wuhan No 1 Hospital, wuhan, China, ¹⁹Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology, wuhan, China, ²⁰The Second Xiangya Hospital of Central South University, Changsha, China, ²¹Department of Rheumatology, First Affiliated Hospital of Medical University Of Anhui, Hefei, China, ²²The First Affiliated Hospital of Nanchang University, Nanchang, China, ²³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁴Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China
Background/Purpose: Adverse events (AE) during treatment in RA patients are unavoidable. Monitoring AEs in real time during long-term treatment is critical for AE detection and…
Abstract Number: 2587 • 2018 ACR/ARHP Annual Meeting
The Impact of Tumor Necrosis Factor Inhibitors on Diabetes Mellitus Among Patients with Inflammatory Arthritis
Santhi Mantravadi¹, Michael D. George² and Alexis Ogdie³, ¹Department of Clinical Pharmacology, Division of Rheumatology, Jefferson University School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Tumor necrosis factor (TNF) is a key inflammatory cytokine in the pathogenesis of psoriatic arthritis (PsA), RA, ankylosing spondylitis (AS), and diabetes mellitus (DM). …
Abstract Number: 561 • 2018 ACR/ARHP Annual Meeting
U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Maxime MA Verhoeven¹, Maria JH de Hair², Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Xavier M Teitsma², Jacob van Laar², Floris PJG Lafeber², Johannes W. J. Bijlsma⁵ and Johannes W. G. Jacobs⁶, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Roche Nederland BV, Woerden, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The U-Act-Early trial was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission, with step-up…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].